Terms: = Kidney tumors AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Treatment
58 results:
1. Clinical Efficacy of Bushen Yiqi Fuzheng Decoction Combined with Sunitinib in the treatment of Postoperative Patients with Renal Cell Carcinoma and Its Influence on Their Immune Function.
Zhang L; Liu L; Zhao L; Yuan X; Wang Y; Yang J
Arch Esp Urol; 2023 Sep; 76(7):538-547. PubMed ID: 37867340
[TBL] [Abstract] [Full Text] [Related]
2. Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.
Figg WD; Fiorini G; Chowdhury R; Nakashima Y; Tumber A; McDonough MA; Schofield CJ
Proteins; 2023 Nov; 91(11):1510-1524. PubMed ID: 37449559
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic role of the immunohistochemical expression of proteins related to the renin-angiotensin system pathway in nonmetastatic clear cell renal cell carcinoma.
Mourão TC; Bezerra SM; de Almeida E Paula F; Rocha MM; Santos VE; Brazão Junior ES; Abreu D; da Costa WH; Zequi SC
Urol Oncol; 2023 Aug; 41(8):359.e1-359.e13. PubMed ID: 37286405
[TBL] [Abstract] [Full Text] [Related]
4. Identifying Prognostic Biomarkers Related to m6A Modification and Immune Infiltration in Renal Cell Carcinoma.
Ye J; Li P; Zhang H; Wu Q; Yang D
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360294
[TBL] [Abstract] [Full Text] [Related]
5. THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.
Kaelin WG
Trans Am Clin Climatol Assoc; 2022; 132():170-181. PubMed ID: 36196173
[TBL] [Abstract] [Full Text] [Related]
6. Resveratrol Nanoparticles Suppresses Migration and Invasion of Renal Cell Carcinoma Cells by Inhibiting Matrix Metalloproteinase 2 Expression and Extracellular Signal-Regulated Kinase Pathway.
Zhu XW; Dong FM; Liu J; Li MS
J Biomed Nanotechnol; 2022 Apr; 18(4):1001-1008. PubMed ID: 35854457
[TBL] [Abstract] [Full Text] [Related]
7. Bioinformatics Study Identified EGF as a Crucial Gene in Papillary Renal Cell Cancer.
Qu G; Wang H; Tang C; Yang G; Xu Y
Dis Markers; 2022; 2022():4761803. PubMed ID: 35655917
[TBL] [Abstract] [Full Text] [Related]
8. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.
Zhang S; Cao M; Hou Z; Gu X; Chen Y; Chen L; Luo Y; Chen L; Liu D; Zhou H; Zhu K; Wang Z; Zhang X; Zhu X; Cui Y; Li H; Guo H; Zhang T
Cancer Lett; 2021 Mar; 501():147-161. PubMed ID: 33383154
[TBL] [Abstract] [Full Text] [Related]
10. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Lee CH; Motzer RJ; Glen H; Michaelson MD; Larkin J; Minoshima Y; Kanekiyo M; Ikezawa H; Sachdev P; Dutcus CE; Funahashi Y; Voss MH
Br J Cancer; 2021 Jan; 124(1):237-246. PubMed ID: 33024271
[TBL] [Abstract] [Full Text] [Related]
11. A seven-gene signature model predicts overall survival in kidney renal clear cell carcinoma.
Chen L; Xiang Z; Chen X; Zhu X; Peng X
Hereditas; 2020 Sep; 157(1):38. PubMed ID: 32883362
[TBL] [Abstract] [Full Text] [Related]
12. Identification of potential novel differentially-expressed genes and their role in invasion and migration in renal cell carcinoma.
Shi SN; Qin X; Wang S; Wang WF; Zhu YF; Lin Y; Zhou ZL; Shi BK; Liu XG
Aging (Albany NY); 2020 May; 12(10):9205-9223. PubMed ID: 32420905
[TBL] [Abstract] [Full Text] [Related]
13. Transcriptomic expression levels of the VHL, timp-3, and RASSF1A genes in renal tumors.
Ure I; Konac E; Alp E; Onen HI; Batur AF; Gonul II; Menevse S; Sozen S
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9313-9320. PubMed ID: 31773698
[TBL] [Abstract] [Full Text] [Related]
14. Anemia of Inflammation with An Emphasis on Chronic kidney Disease.
Begum S; Latunde-Dada GO
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31614529
[TBL] [Abstract] [Full Text] [Related]
15. [Differential Diagnosis of Erythrocytosis - Background and Clinical Relevance].
Wille K; Sadjadian P; Griesshammer M
Dtsch Med Wochenschr; 2019 Jan; 144(2):128-135. PubMed ID: 30674061
[TBL] [Abstract] [Full Text] [Related]
16. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
Khong B; Lawson BO; Ma J; McGovern C; Van Atta JK; Ray A; Khong HT
BMC Cancer; 2018 Oct; 18(1):1007. PubMed ID: 30342473
[TBL] [Abstract] [Full Text] [Related]
17. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
[TBL] [Abstract] [Full Text] [Related]
18. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in kidney Cancer.
Liang J; Liu Z; Zou Z; Tang Y; Zhou C; Yang J; Wei X; Lu Y
Sci Rep; 2018 Apr; 8(1):6570. PubMed ID: 29700419
[TBL] [Abstract] [Full Text] [Related]
19. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.
Nakamura M; Zhang Y; Yang Y; Sonmez C; Zheng W; Huang G; Seki T; Iwamoto H; Ding B; Yin L; Foukakis T; Hatschek T; Li X; Hosaka K; Li J; Yu G; Wang X; Liu Y; Cao Y
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9635-E9644. PubMed ID: 29078273
[TBL] [Abstract] [Full Text] [Related]
20. Expression of the Major Vault Protein (MVP) and Cellular Vault Particles in Fish.
Margiotta AL; Bain LJ; Rice CD
Anat Rec (Hoboken); 2017 Nov; 300(11):1981-1992. PubMed ID: 28710803
[TBL] [Abstract] [Full Text] [Related]
[Next]
